ruled that once invasive treatment has been intensified to save the life of a critical patient, lifesaving equipment cannot be turned off unless the physicians are certain about the inevitability of death. The Islamic religion concepts concerning DNR decision have been clarified by the Presidency of the Administration of Islamic Research and Ifta, Riyadh, Kingdom of Saudi Arabia, in their fatwa No. 12086 issued on 30.6.1409 (Hijra) (1988 [AD] ). The fatwa states that: "If three knowledgeable and trustworthy physicians agreed that the patient condition is hopeless; the life supporting machines can be withheld or withdrawn. The family members' opinion is not included in decision making as they are unqualified to make such decisions." [3] Actually, no obstacles do exist in the implementation of that prerequisite in intensive care units in Muslim countries. Islamic law governs EOL legal issues in Muslim countries as there is a specific legal terminology, derived from the Qura'an (holy book of Muslims) and Sunnah (verses of Prophet Muhammad [peace be upon him]), which is used to settle conflicts in EOL care. This contrasts with the nonMuslim countries, particularly in America and Europe, which has a secular system of law that informs EOL issues. Hence, it would be difficult for Muslims who constitute minorities in these countries to follow Qura'an and Sunnah laws in making EOF decisions for terminally-ill patients.
Comments on "Candida glabrata candidemia; an emerging threat in critically ill patients"
Sir,
The article "Candida glabrata candidemia; An emerging threat in critically ill patients" very well highlights the importance of this emerging species. [1] Due to delay in time to positivity for blood culture, empirical antifungal therapy is an important strategy in the management of invasive candidiasis, more so for C. glabrata infection. Appropriate empirical therapy requires identification of high risk group. In the present study, authors have reported broad spectrum antibiotic, mechanical ventilation, central venous catheter, diabetes mellitus and age >65 years as risk factors for C. glabrata candidemia. We agree with Chakrabarti's view that due to lack of control group in the study, it is difficult to draw any inference regarding the risk factors. [2] At least two authors have attempted to develop risk model to predict C. glabrata candidemia.
Tapia et al. studied 246 cases of candidemia, out of which 68 cases were due to C. glabrata. [3] Four factors independently associated with C. glabrata candidemia were absence of renal failure, <7 days in the hospital, abdominal surgery and fluconazole use. The model had moderately good discriminating ability between C.glabarata candidemia and non C. glabrata candidemia (c-statistic value 0.727 [95% confidence interval: 0.635-0.775]).
Another risk prediction model was developed by Cohen et al. in a study including 48 C. glabrata candidemia patients and 106 had nonglabrata fungemia. [4] The model identified six factors independently associated with C. glabrata candidemia. These were age >60 years, recent abdominal surgery, interval from intensive care unit admission to first positive blood culture <7 days, recent use of cephalosporins, solid tumor, and absence of diabetes mellitus. The model had good discriminating ability (c-statistics value 0.89).These models require external validation before they can be generalized in different cohorts.
Both above described models have identified gastro surgery as an independent risk factor for C. glabrata candidemia. [3, 4] C. glabrata is a frequent gut colonizer in hospitalized patients and can disseminate to cause candidemia in susceptible host. It has been shown in animal model that gut of antibiotic-treated mice can act as a reservoir for C. glabrata. It would be enlightening if the authors can report the data regarding, nature of surgeries done in the surgical group.
Hospitalized patients are frequently colonized with Candida. Risk of candidemia increases with increase in density of colonization and number of colonized sites. [5] The method used for identifying urine as the most common source of C. glabrata candidemia needs to be mentioned in the study. Authors have stated that candiduria is a useful indicator for systemic candidiasis, but it is unclear from the results that what were the other sites looked for. Interpreting the source of candidemia without studying different sites for colonization and typing the strain can give misleading results.
Local epidemiology is important to guide empirical antifungal therapy. More studies are needed to identify the risk factors for C. glabrata infection and colonization as well as to conduct external validation of already existing risk models. 
Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury
Sir, We read with interest the article by Anish Kumar et al. [1] It is an extremely important issue in critical care settings considering the incidence and high mortality rates associated with sepsis and the subsequent development of acute kidney injury (AKI). The antibiotics are one of the most important armamentarium in dealing with this problem. If we do not get the right dose at right time then it not only increases mortality, but also leads to subsequent development of infection with resistant organisms. The article adds to our improved understanding of the usage of antibiotics in septic AKI patients. The article has very well elaborated the factors that can affect the dosing of the antibiotics and how to give the appropriate dosage for most of the commonly used antibiotics.
There has been a significant epidemiological shift in the resistance patterns in intensive care unit (ICU) worldwide. Multidrug-resistant Pseudomonas and Acinetobacter have been the prototypical nosocomial pathogens for the past few decades. These organisms may be eclipsed by a rapidly growing global epidemic of cephalosporin and carbapenem-resistant Enterobacteriaceae. These organisms have been detected in India since 2006. [2] They continue to be a major source of nosocomial infections especially in Indian ICUs.
The use of colistin and tigecycline to deal with the changed epidemiology has increased in ICUs. [3] These drugs have their own unique pharmacokinetic and pharmacodynamic profile. This review does not highlight about the factors that may affect the pharmacokinetic s and dynamics of these drugs in AKI. The dosing regimen of colistin may also vary with different modalities of renal replacement therapy, and needs to be discussed as recommended by different authors. [4, 5] The renal toxicity of colistin is said to be overestimated in past studies. We need new studies to look for dosing of colistin especially in septic AKI patients and reviews must address this issue.
